WallStSmart
ALNY

Alnylam Pharmaceuticals Inc

NASDAQ: ALNY · HEALTHCARE · BIOTECHNOLOGY

$309.49
+2.76% today

Updated 2026-04-30

Market cap
$40.19B
P/E ratio
129.82
P/S ratio
10.82x
EPS (TTM)
$2.32
Dividend yield
—
52W range
$246 – $496
Volume
1.1M
OverviewPrice TargetsFinancialsValuationInsidersEarnings

Alnylam Pharmaceuticals Inc (ALNY) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current
$309.49
Consensus
$471.93
+52.49%
2030 Target
$1,084.09
+250.28%
DCF
$2,113.13
+84.75% MoS
28 analysts:
10 Buy6 Hold0 Sell

Management guidance

CEO Yvonne Greenstreet outlined 'Alnylam 2030' strategy targeting 25% revenue CAGR through 2030 and aiming for $4.4B-$4.7B in 2026 revenue. The company projects 30% operating margins expanding to mid-40% levels, with 30% of sales reinvested in R&D. Management expects continued momentum from AMVUTTRA (TTR franchise) and expansion into new tissues including cardiovascular indications.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range
Bull case (2030)
$1,817.45
$11.9B Rev × 20x P/S
Base case (2030)
$1,084.09
$11.9B Rev × 12x P/S
Bear case (2030)
$733.36
$11.9B Rev × 8x P/S

Financial forecast — research-backed

Metric2023202420252026 (E)2027 (E)2029 (E)2030 (E)
Revenue$1.8B$2.2B$3.7B$4.5B$6.0B$9.7B$11.9B
Revenue growth—23.0%65.2%22.6%30.8%26.1%23.8%
EPS$-3.56$-1.09$3.63$7.46$11.16$19.30$23.90
P/S ratio———12.0x12.0x12.0x12.0x
Implied price———$414.51$542.05$860.90$1,084.09

Catalysts & risks

Growth catalysts
+ AMVUTTRA (vutrisiran) continued expansion in ATTR-CM with AI-enabled diagnostic pathways through Viz.ai partnership driving earlier patient identification
+ Zilebesiran Phase 3 CVOT completion for hypertension management - potential multi-billion dollar cardiovascular market expansion
+ Tenaya Therapeutics collaboration exploring 15 cardiovascular RNAi targets - pipeline diversification beyond rare diseases
+ Pipeline progression: cemdisiran, mivelsiran, and other candidates advancing through clinical development
+ Operating margin expansion path to 30%+ as revenue scales and manufacturing efficiencies realized
Key risks
- High valuation (136.8x P/E) creates significant downside if growth targets missed - stock already down 33% from 52W high
- AMVUTTRA concentration risk: TTR franchise represents majority of revenue; pricing pressures in rare disease market increasing
- Competitive threats: other RNAi platforms and gene therapy alternatives emerging in ATTR and cardiovascular indications
- Margin compression concerns: gross margins of 81.6% may face pressure from manufacturing scale-up and competitive pricing
- Clinical execution risk: zilebesiran Phase 3 CVOT outcome; multiple pipeline programs must advance successfully through 2030

Methodology

Alnylam Pharmaceuticals Inc's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 28 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 7, 2026.